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Importance 23
The type 3 secretion system (T3SS) is a nanomachine required for virulence of many 24 bacterial pathogens that infect humans. The system delivers bacterial virulence proteins 25 into the cytosol of human cells, where the virulence proteins promote bacterial infection. 26
The T3SS forms a translocon pore in the membrane of target cells. This pore is the 27 portal through which bacterial virulence proteins are delivered by the T3SS into the 28 eukaryotic cytosol. The pore also regulates the secretion of these virulence proteins. 29
Our work defines the topology of translocon pore proteins in their native context during 30 infection, resolves previously conflicting reports about the topology of the Shigella 31 translocon pore protein IpaC, and provides new insights into how interactions of the 32 pore with the T3SS likely produce signals that activate secretion of virulence proteins. 33
Introduction 34
The type 3 secretion system is a specialized nanomachine required for the virulence of 35 more than 30 bacterial pathogens (1). The T3SS translocates bacterial virulence 36 proteins, known as effector proteins, from the bacterial cytosol into the cytosol of 37 eukaryotic cells. The T3SS is composed of a base that spans the two bacterial 38 membranes (2), a needle that is anchored in the base and extends away from the 39 bacterial surface (2,3), and a tip complex that prevents non-specific secretion (4, 5) . 40
Upon contact of the tip complex with a eukaryotic cell, the T3SS secretes two bacterial 41 proteins that embed in the plasma membrane (6), where they assemble into a hetero-42 oligomeric pore, known as the translocon pore (3). The translocon pore is essential for 43 T3SS activity; it functions as a conduit through which bacterial virulence proteins 44 ("effectors") traverse the plasma membrane to gain access to the eukaryotic cytosol (3), 45
and it participates in defining the timing of the secretion of these effectors by the T3SS 46 (7). 47 are predicted to interact with the needle, but it is uncertain how this interaction occurs, 57 as the topology of IpaC in the plasma membrane is controversial. The two previous 58 studies that investigated IpaC topology used purified recombinant IpaC. These studies 59
showed IpaC inserting into the membrane with its N-terminus on the extracellular 60 surface of the plasma membrane, but came to opposing conclusions about the location 61 of the C-terminus; interactions of IpaC with artificial liposomes concluded that IpaC 62 contained a single transmembrane-helix with the C-terminus present in the liposome 63 lumen (9), whereas investigation of purified IpaC incorporating into macrophage 64 membranes concluded that IpaC contained two transmembrane -helixes with the C-65 terminus accessible on the extracellular surface of the macrophage (10). 66
Here we defined the topology of the Shigella translocon protein IpaC during bacterial 67 infection following its native delivery into the plasma membrane by the T3SS. Using 68 single cysteine accessibility mutagenesis, we defined a topological map of IpaC 69
showing that the amino terminal region is extracellular, that the carboxy terminal region 70 is in the cytosol, and that a single transmembrane-helix is present. Furthermore, to 71 test whether this topology is conserved among IpaC homologs in other pathogens that 72 require T3SS for virulence, the accessibility of analogous residues for the Salmonella 73 pore protein SipC was tested. We found that the overall topologies of IpaC and SipC are 74 similar. However, we observed subtle differences between the two proteins in the 75 accessibility of the transmembrane-helixes and the C-terminal regions that may 76 contribute to organism-specific functional differences of these T3SSs during infection.
Results 78
transcription-based reporter of T3SS activity (TSAR, (7, 16) ); following the secretion of 123 the translocon pore proteins and the bacterial effector protein OspD through the T3SS, 124 the TSAR reporter produces GFP in the bacterium. The promoter for GFP is regulated 125 by MxiE, which is activated upon secretion of OspD (16). S. flexneri producing cysteine 126 substituted IpaC derivatives activated the T3SS to secrete effector proteins at 127 efficiencies similar to WT IpaC (Figs. 2A, F , and G, and S1A). Both the absolute number 128 per cell of bacteria with active secretion ( Fig. 2A and F ) and the percentage of docked 129 bacteria with active secretion ( Fig (Fig. S1B) . In sum, substitution of selected IpaC residues 142 with cysteine did not significantly alter either IpaC activity or T3SS function during S.
Accessibility of IpaC residues in membrane-embedded S. flexneri translocon 145
pores. To measure the accessibility of IpaC residues in translocon pores embedded in 146 the plasma membrane of host cells, site-directed labeling by methoxypolyethelene 147 glycol maleimide (PEG5000-maleimide) was performed with the library of IpaC cysteine 148 substitution derivatives characterized above. Because PEG5000-maleimide is 149 membrane impermeant (12) and is too big to pass entirely through the translocon pore 150 (3,7), this approach specifically assesses the accessibility of the cysteine residue to the 151 extracellular surface of the eukaryotic cell. Cysteine substitutions within the N-terminal 152 domain (residues 1-99) of IpaC labeled efficiently with PEG5000-maleimide, as 153 demonstrated by a distinct shift to a slower migrating position on SDS-PAGE (Fig. 3) . 154
Efficient labeling was also observed for one of the four residues tested within the 155 putative transmembrane-helix (residues 100-120) (Fig. 3) ; labeling at IpaC A106C 156 was efficient, whereas labeling of the three other residues in the putative 157
transmembrane-helix that were tested (S101C, S108C, and A119C) was essentially 158 undetectable. The labeling of IpaC cysteine substitutions C-terminal to the putative 159 transmembrane-helix was weak, except among substitutions of the 15 residues 160 closest to the C-terminus (residues 349-363) (Fig. 3) . All cysteine substitutions of IpaC, 161 including the substitutions in the putative transmembrane-helix and the substitutions 162 C-terminal to it, were readily labeled by PEG5000-maleimide when the labeling was 163 performed on IpaC in solution following secretion from bacteria in vitro (Fig. S2A-B) , 164
indicating that the lack of labeling observed during infection was a function of 165 inaccessibility due to the membrane-embedded state rather than to fundamental 166 inaccessibility of the residue in the protein per se. When labeling was performedfollowing permeabilization of the plasma membrane, accessibility of IpaC residues near 168 the C-terminus was similar to the accessibility of the residues in the N-terminal domain 169 (Fig. S2C-D) , which demonstrates that under non-permeabilizing conditions, the plasma 170 membrane inhibited access of PEG5000-maleimide to the residues near the C-171 terminus. To test whether docking of the needle on the translocon pore inhibited 172 labeling of residues near the C-terminus, we compared the accessibility of IpaC A358C, 173 which is close to the C-terminus (R362), with that of S17C, a residue in the N-terminal 174 domain, in the presence and absence of intermediate filaments. We previously showed 175 that in the absence of intermediate filaments, docking does not occur but translocon 176 pores form at wild-type levels (7). Since docking occurs through interactions of the 177 needle tip complex with the pore (15), in the absence of intermediate filaments, pores 178 form without a needle tip complex associated with the pore. The accessibility of A358C 179 was similar in the presence and absence of intermediate filaments (Fig. S3) , and the 180 accessibility of S17C was greater than the accessibility of A358C and was also 181 independent of intermediate filaments (Fig. S3 ). These data show that the engagement 182 of the T3SS needle and/or tip complex with the translocon pore does not alter the 183 accessibility of residues near the C-terminus of IpaC. Altogether, these results indicate 184 that, whereas IpaC sequences immediately C-terminal to the putative 185 transmembrane-helix are intracellular, some or all of the 15 residues closest to the C-186 terminus of IpaC are partially accessible from the extracellular surface of the plasma 187 membrane. indicates that SipC and IpaC are sufficient to direct the bacterium to distinct intracellular 201
T3SS (1

niches (23). 202
To explore whether the observed functional differences between IpaC and SipC were 203 associated with differences in protein topology in the plasma membrane, we compared 204 the accessibility of SipC residues with that of IpaC residues. Like IpaC, native SipC 205 lacks cysteines. The putative secondary structure of SipC is very similar to that of IpaC, 206 with a putative N-terminal extracellular domain (residues 1-119), a putative 207 transmembrane -helix (residues 120-140), and C-terminal to the transmembrane-208 helix, a putative coiled-coil domain (residues 293-320) (Fig 4A) . The second putative 209 transmembrane span identified in IpaC was not clearly delineated by in silico analyses 210 of SipC. We substituted cysteines at residues of SipC that were analogous to those 211 chosen for substitution in IpaC ( Fig. 4B-C) . During S. Typhimurium infection of HeLa 212 cells, the accessibility of these residues from the extracellular surface of the plasmamembrane was tested using the same method used for IpaC, site-directed labeling with 214
PEG5000-maleimide. As observed for IpaC, substitutions in the N-terminal domain of 215
SipC labeled efficiently ( Fig. 4D-E) . In contrast to our findings for IpaC, labeling was not 216 observed for any other SipC substitution tested ( Fig. 4D-E) ; this included SipC A126C, a 217 cysteine substitution at a residue within the SipC putative transmembrane-helix that is 218 analogous to IpaC A106C, which labeled efficiently with PEG5000-maleimide, and 219 cysteine substitutions at residues within the C-terminal 15 amino acids of SipC, which in 220
IpaC labeled with intermediate efficiency.
221
As for IpaC, SipC tolerated substitution with cysteine at numerous sites along the length 222 of the protein. The SipC cysteine derivatives were produced in Salmonella at levels 223 similar to WT SipC (Fig. S5A) . Moreover, each cysteine substitution derivative 224 supported S. Typhimurium docking to HeLa cells (Fig. S5B) . Thus, the differences in 225 labeling observed for cysteine substitutions of IpaC compared to cysteine substitutions 226 of SipC were not due to altered function of the SipC derivatives. 227
These data suggest that the overall topologies of plasma membrane-embedded SipC 228 and plasma membrane-embedded IpaC are similar. For each protein, the N-terminal 229 domain is extracellular, a single transmembrane-helix is present, and the C-terminus 230 is intracellular (Fig. 5 ). Despite the similarities in overall topology, the differences 231 observed in the accessibility of substitutions close to the C-termini of the two proteins 232 suggest that subtle topological or structural differences exist in the transmembrane-233 helix and C-terminal regions. The differences we observe between the two proteins in 234 the context of plasma membrane-embedded translocon pores may be relevant to
Discussion 237
The T3SS is essential for the pathogenesis of many important human bacterial 238 pathogens, and the translocon pore is essential for T3SS function. To generate insights 239 into how the translocon pore participates in the signaling that activates secretion of 240 effector proteins, we defined the topology of IpaC in the membrane of human-derived 241 cells. To our knowledge, this represents the first detailed topological analysis of a type 3 242 translocon pore protein following its native delivery to the plasma membrane. We show 243 that the N-terminal region of IpaC is extracellular and the C-terminal region of IpaC is in 244 the host cytosol. Moreover, we observed a similar overall topology for SipC, the IpaC 245 homolog in Salmonella. The observations that the N-terminal region of IpaC is located 246 on the extracellular side of the plasma membrane is consistent with previous 247 observations investigating the interactions of recombinant IpaC with the membrane 248 (9,10). 249
The labeling of A106C in the transmembrane span indicates that the outer portion of the 250 pore channel is at least 4.4 nm wide, the approximate size of PEG5000-maleimide. 251
Moreover, the lack of labeling for other residues in the transmembrane-helix of IpaC 252 suggest that towards the cytosolic side of the plasma membrane, either the lumen of the 253 pore becomes narrower, such that the PEG5000-maleimide is precluded from 254 accessing the IpaC residues, and/or that other IpaC residues do not line the pore 255 interior. If the latter were true, it could indicate that IpaB residues line the bulk of the 256 channel.
secondary structure (residues 121-308) and a predicted coiled-coil domain (residues 259 309-344). The minimal accessibility to PEG5000-maleimide of IpaC cysteine 260 substitutions within these sequences strongly suggests that these sequences, including 261 the coiled-coil domain, lie within the cytosol and that residues 100-120 constitute a 262 transmembrane-helix and the only transmembrane-helix in the protein. By 263 extension, these data suggest that all of IpaC C-terminal to this transmembrane-helix 264 lies on the cytosolic side of the plasma membrane (Fig. 5A) . Additional attempts to 265 directly assess the location of the C-terminal region of IpaC, including limited 266 proteolysis, incorporation of enzymatic cleavage sites that would specifically function 267 within the intracellular environment, and immunolabeling with monoclonal antibodies 268 specific for C-terminal or N-terminal sequences, were uninformative. 269
Cysteine substitutions in the C-terminal 15 amino acids of IpaC were weakly but 270 reproducibly accessible from the outside of the cell, suggesting that they are present 271 within the pore lumen. Consistent with this possibility, crosslinking studies showed that 272 residues in the C-terminal region of the Pseudomonas translocon pore protein PopD, a 273 homolog of IpaC, interact with the Pseudomonas T3SS tip complex protein (15), which 274 docks onto the extracellular face of the translocon pore. Of note, atomic force microcopy 275 studies suggest that the lumen of the E. coli translocon pore is shaped like a funnel, 276 with the narrower portion of the funnel closer to the cytosolic side of the plasma 277 membrane (24). If the Shigella translocon pore is shaped similarly to the E. coli 278 translocon pore, the detection of PEG5000-maleimide labeling of cysteine substitutions 279 near the C-terminus of IpaC could be consistent with these residues looping back from 280 the cytosolic side of the plasma membrane into the pore lumen where they might bepositioned to engage the tip complex. If this is the case, these C-terminal domain 282 residues might contribute directly to the narrowest portion of the funnel shape of the 283 pore. 284
Our data support a model of the native topology of IpaC in mammalian plasma 285 membranes in which the N-terminal domain of IpaC is extracellular, a single 286 transmembrane-helix crosses the plasma membrane, the region C-terminal to the 287 transmembrane-helix is present within the cytosol, and the C-terminal 15 amino acids 288 of IpaC re-enter the pore interior (Fig 5A) . 289
The overall topology of SipC and IpaC was similar, with the N-terminus of SipC 290 extracellular and the C-terminus intracellular (Fig. 5B) . Both IpaC and SipC support 291 bacterial docking to cells (7, 8) . Our models place the N-terminal regions of these 292 proteins at the cell surface where these sequences would be positioned adjacent to the 293 T3SS needle as it docks on the extracellular face of the translocon pore. This proximity 294 would facilitate the involvement of the N-terminal domains of these proteins in docking 295 and activation of effector secretion. Moreover, for both Shigella IpaC and Salmonella 296
SipC, an interaction with intermediate filaments is required for bacterial docking (7). For 297
IpaC, we previously demonstrated that sequences adjacent to the protein's C-terminus 298 are required for this interaction with intermediate filaments (7). Our models for IpaC and 299
SipC place the extreme C-terminal regions of these proteins in the cytosol of the 300 eukaryotic cell, adjacent to the intermediate filaments of the cell cortex with which they 301 interact.
The similarity between the overall topology of IpaC and that of SipC suggests that the 303 mechanism(s) required to deliver the two proteins into the membrane, multimerize into 304 the pore, interact with the lipid membrane, support effector translocation, and generate 305 signals to activate secretion may be similar. However, in contrast to the accessibility of 306 some cysteine substitutions in the C-terminal region of IpaC, substitutions near the C-307 terminus of SipC were completely inaccessible. This indicated that multiple topologies of 308 SipC do not occur at an efficiency that was detectable in this assay and, by extension, 309 that the weak labeling observed at IpaC substitutions near the C-terminus are unlikely to 310 be the result of a minority population of membrane-embedded IpaC having an alternate 311 topology. In addition, whereas the two proteins are homologs, they display functional investigations into translocon pore structure will inform the molecular mechanisms that
Materials and Methods 325
Bacterial culture. Strains used in this study are described in Table 1 . The S. flexneri 326 wild type strain was serotype 2a strain 2457T (26) , and all mutants were isogenic 327 derivatives of it. S. flexneri strains were cultured in trypticase soy broth (Benton 328 Dickenson) at 37C. ipaC derivatives were encoded on the plasmid pBAD33 and their 329 expression was driven from the pBAD promoter, induced with 1.2% arabinose. The 330 sequences of primers used for PCR and sequencing are available from the authors 331 upon request. The wild type Salmonella enterica serovar Typhimurium strain was 332 SL1344, and all S. Typhimurium mutants used in this study were isogenic derivatives of 333 it. Salmonella strains were cultured in trypticase soy broth at 37C. sipC derivatives 334 were encoded on the plasmid pBAD18 and their expression was driven from the pBAD 335 promoter, induced with 1.2% arabinose. 336
Cell culture. Mouse embryonic fibroblasts were kindly provided by Victor Faundez 337 (Emory), and HeLa (CCL2) cells were obtained from ATCC. All cells were cultured in 338 Dulbecco's Modified Eagles Media (DMEM) supplemented with 0.45% glucose and 10% 339 heat-inactivated fetal bovine serum (FBS); they were maintained at 37C in humidified 340 air containing 5% CO 2 . All cells in the laboratory are periodically tested for mycoplasma; 341 cells that test positive are treated or discarded. 342 Secretion assays. To assess the ability of the type 3 secretion system to secrete 343 proteins in the absence of eukaryotic cells, the T3SS was artificially activated by 344 addition of Congo red (7, 14, 27) . Overnight cultures were back diluted, induced wherewere normalized by OD 600 , resuspended in PBS containing 1.2% arabinose, where 347 appropriate, and 10 M Congo red, and incubated in a water bath at 37C for 45 min. 348
The bacteria were removed by centrifugation, and the resulting supernatant containing 349 the secreted proteins was collected. 350
Erythrocyte lysis assay. Pore formation in sheep erythrocyte membranes was 351 monitored by assessing the efficiency of erythrocyte lysis (3,7). Briefly, 10 8 erythrocytes 352
were washed with saline and infected with S. flexneri at a multiplicity of infection (MOI) 353 of 25 in 30 mM Tris, pH 7.5. The bacteria were centrifuged onto the erythrocytes at 354 2000 g for 10 minutes at 25C. Bacteria and erythrocytes were cultured together for 30 355 minutes at 37C in humidified air with 5% CO 2 . The bacteria and erythrocyte co-cultures 356 were mixed by pipetting and then centrifuged again at 2,000 g for 10 minutes at 25C. 357
As a positive control for lysis, an aliquot of uninfected erythrocytes was treated with 358 0.02% SDS and then centrifuged. The supernatants were collected, and the abundance 359 of hemoglobin released was measured spectrophotometrically at A 570 using a Wallac 360
1,420 Victor 2 (Perkin Elmer). 361
Translocation and docking. Mouse embryonic fibroblasts were seeded at 3x10 5 cells 362 per well on coverslips in a 6-well plate. The cells were infected with exponential phasereporter, which expresses GFP when the bacterial effector OspD is secreted through 365 the T3SS (16), is an indicator of active T3SS secretion. Bacteria were centrifuged onto 366 cells at 800 g for 10 minutes at 25C. The bacteria and cells were co-cultured for an 367 additional 30 minutes at 37C in humidified air with 5% CO 2 . Cells were washed threetimes with PBS, fixed with 3.7% paraformaldehyde for 20 minutes at 25C, and washed 369 again with PBS. DNA was stained with Hoechst. Four random microscopic fields per 370 experimental condition were imaged by fluorescent microscopy using a Nikon Eclipse 371 TE-300 with appropriate filters. All bacteria produced mCherry, and bacteria in which 372 T3SS secretion was activated produced GFP (16 NaCl, 1.2% arabinose, and 2.5 mM PEG5000-maleimide. The bacteria were centrifuged 403 onto the cells at 800 g for 10 minutes at 25C and incubated at 37C in humidified air 404 with 5% CO 2 for 20 min. Cells were then harvested and plasma membrane-enriched 405 fractions were isolated, as done previously (7, 30) . Briefly, the cells were washed three 406 times with ice-cold 50 mM Tris, pH 7.4, and scrapped in 50 mM Tris, pH 7.4, containing 407 protease inhibitors (Protease inhibitor cocktail, complete mini-EDTA free, Roche). 408
Scrapped cells were pelleted at 3,000 g for 3 minutes at 25C. The pelleted cells were 409 resuspended in 50 mM Tris, pH 7.4, containing protease inhibitors and 0.2% saponin, 410 and were incubated on ice for 20 min. For experiments testing the accessibility of IpaC 411 residues in the presence of membrane permeabilization, PEG5000-maleimide was 412 added in the presence of 0.2% saponin and not included during the infection. The 413 suspension was centrifuged at 21,000 g for 30 minutes at 4C. The supernatant, whichcontains the cytosol fraction, was decanted into a fresh tube. The pellet was 415 resuspended in 50 mM Tris, pH 7.4, containing protease inhibitors and 0.5% Triton X-416 100, incubated on ice for 30 minutes, and centrifuged at 21,000 g for 15 minutes at 4C. 417
The supernatant from this spin contained the membrane fraction, and the pellet 418 consisted of the detergent insoluble fraction, which included intact bacteria. The 419 efficiency of PEG5000-maleimide labeling was monitored by assessing the gel shift of 420
IpaC or SipC by western blot. Antibodies used for western blots: rabbit anti-IpaC (gift 421 from Wendy Picking, 1:10,000), rabbit anti-GroEL (Sigma, G6352, 1:1,000,000), rabbit 422
anti-Caveolin-1 (Sigma, cat # C4490, 1:1000), chicken anti-vimentin (BioLegend, cat # 423 919101, 1:5,000), mouse anti-SipC (Gift from Jorge Galán, 1:10,000), goat anti-rabbit showing the putative secondary structure of IpaC (7,9). Putative transmembrane span, 560 residues 100-120 (solid zig-zag), predicted by in silico analyses and experimental data 561 Data are the mean ± SEM; dots represent independent experimental replicates. **, 598 p<0.01; ***, p<0.001 (Student's t-test). Stable docking of bacteria and secretion via the 599 T3SS for each strain producing an IpaC cysteine substitution derivative was not 600 statistically different from that of the strain producing WT IpaC (by ANOVA). Densitometry analysis of IpaC-PEG5000 bands from three independent experiments for 610 each cysteine substitution derivative; mean ± SEM; dots represent independent 611 experimental replicates. 612 
